EUCTR2019-003024-20-ES进行中（未招募）1 期
Multicenter, double-blind, randomized clinical trial to evaluate and compare the efficacy and safety of Hemorrane® Plus (Hemorrane® + benzocaine) with Hemorrane® and with placebo in patients with grade I and II hemorrhoids.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 185
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age: over 18 years.
- •2. Sex: both sexes.
- •3. Patients with grade I and II hemorrhoids.
- •4. Patients with pain assessed according to Visual Analogue Scale = 5 points.
- •5. Patients with pruritus and burning-sting evaluated according to Visual Analogue Scale = 5 points.
- •6. The patient must commit to comply with the hygienic-dietary measures established for the general management of hemorrhoids.
- •7. Urinary test of negative pregnancy in women.
- •8. Patients with adequate level for understanding the study.
- •9. The patient must have voluntarily signed the Informed Consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 185
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who have used other topical antihemorrhoids or other topical agents applicable in the same anorectal area for at least one week before the start of the study (Visit 1, day 1), nor their use throughout the study
- •2. Hemorrhoidal surgical intervention that is scheduled from Visit 1 (day 1) to the follow-up visit Visit 3 (day 15).
- •3. Severe liver disease (Child-Pugh C).
- •4. Severe or terminal renal failure documented in the patient's medical history.
- •5. Moderate to severe cardiovascular disease documented in the patient's medical history.
- •6. History of hypersensitivity to any of the active ingredients or components of the products under investigation.
- •7. Active hemorrhoidal hemorrhage or for any other cause.
- •8. Patients with other pathologies with symptoms similar to hemorrhoidal disease, and patients with more serious pathologies that may cause rectorrhagia.
- •9. Patients with bacterial, viral and / or fungal infections of the perianal region. 10. Have the diagnostic test for pancreatic puncture with bentiromide scheduled from Visit 1 (day 1) to the follow-up visit Visit 3 (day 15).
- •11. Be on treatment with any of the prohibited concomitant medications (sulfonamides, cholinesterase inhibitors, local ester anesthetics) for at least one week before the start of the study (Visit 1, day 1), or its use throughout the study.
- •12. Any other medical and / or therapeutic circumstance considered by the researcher that prevents adequate follow-up and / or adequate evolution of the response to the study treatments.
- •13. Pregnant women or positive pregnancy test, and lactating women.
- •14. Women of childbearing age who do not undertake to take the pregnancy test and use valid contraceptive methods during the study and up to one week after the end of the study. The following are considered valid contraceptive methods: barrier method (diaphragm, condom), intrauterine device (IUD), vasectomized couple, sexual abstinence, hormonal contraceptives, intrauterine system (SIU), bilateral tubal occlusion.
- •15. HIV positive patients known in the last five years.
- •16. Patients with active cancer process in the last five years.
- •17. Patients who have received an investigational drug (including vaccines) or have used an invasive medical device under investigation in the last 30 days prior to the start of the selection phase or are currently participating in another clinical trial.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate if treatment with calcifediol (vitamin D analog) reduces the number of hospital admissions in patients with COVID-19.EUCTR2021-000316-31-ESFAES FARMA S.A.804
进行中（未招募）
1 期
Study to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.MedDRA version: 15.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple sclerosisEUCTR2012-001965-34-ESServicio de Neurología, HU. Germans Trias i Pujol
进行中（未招募）
不适用
Comparative clinical study on the efficacy and safety of an already approved medicinal product for treatment of actinic keratosis (disease/impairment of the skin by UV light) with a new medicinal product that contains the same active substance and a product without the active substance (vehicle)MedDRA version: 17.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersActinic keratosisEUCTR2014-001621-33-DEDermapharm AG
进行中（未招募）
不适用
A randomized, controlled, multicenter clinical trial comparing the efficacy of Peginterferon alfa-2a and ribavirin and metformin versus Peginterferon alfa-2a and ribavirin for the treatment of naïve patients with chronic hepatitis C (CHC) and insulin resistance. - NDCHRONIC ACTIVE HEPATITIS C ASSOCIATED WITH INSULIN RESISTANCEMedDRA version: 6.1Level: PTClassification code 10019744EUCTR2005-003853-29-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
招募中
1 期
A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathyIgA nephropathyITMCTR2100004723Peking University First Hospital